Comparison · NCT01795859-75dcabea
SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC). Trial comparisons, record NCT01795859-75dcabea. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01795859-75dcabea
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.511 | 0.37 | 0.65 | wilson | |
| Risk in group 2 | 0.2 | 0.109 | 0.338 | wilson | |
| Risk difference, group 1 minus group 2 | 0.311 | 0.114 | 0.478 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.56 | 1.33 | 4.9 | log | |
| Odds ratio, group 1 over group 2 | 4.18 | 1.64 | 10.7 | log | |
| Number needed to treat, for one more participant with the outcome on SD-809 Tablets than on SD-809 Placebo | 3.21 | 2.09 | 8.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SD-809 Tablets | SD-809: SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). | 23 | 45 | OG000 |
| Group 2 | SD-809 Placebo | Placebo: Placebo tablets are identical in appearance to SD-809 tablets. | 9 | 45 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC)
- Description
- A treatment success is defined as Much or Very Much Improved at the Week 12 visit. The PGIC is a 7-point Likert Scale, ranging from very much worse to very much improved
- Time frame
- 12 weeks
- Population
- The Modified ITT (mITT) Population was defined as all subjects in the ITT Population who received study drug and had at least one post baseline assessment.
Source ClinicalTrials.gov
Trial
- Title
- First Time Use of SD-809 in Huntington Disease
- NCT number
- NCT01795859
- Phases
- PHASE3
- Conditions
- Chorea
- Interventions
- SD-809, Placebo
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Results first posted
- 2017-08-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01795859?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01795859-75dcabea